Composition containing at least one inhibitor of the enzyme 3-beta-HSD

• US 20030027772A1
• Filed: 05/30/2002
• Published: 02/06/2003
• Est. Priority Date: 05/30/2001
• Status: Abandoned Application

• Current Assignee: L'Oreal SA
• Original Assignee: L'Oreal SA
• Inventors: Breton, Lionel
• Application Number:
  US10/157,152
• Publication Number:
  US 20030027772A1
• Time in Patent Office: Days
• US Class Current: 514/27
• CPC Class Codes: A61K 2800/782 Enzyme inhibitors; Enzyme antagonists
• CPC Class Codes: A61K 2800/92 Oral administration
• CPC Class Codes: A61K 8/498 having 6-membered rings or their condensed derivatives, e.g. coumarin
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations

Abstract

The invention relates to a composition for topical application or oral administration, containing an effective quantity of at least one inhibitor of the enzyme 3β-hydroxysteroid dehydrogenase. This composition is designed in particular for the treatment of certain effects of chronological ageing and photo-ageing of the skin.

Claims

1. A composition suitable for topical application or oral administration, comprising an effective amount of at least one inhibitor of the enzyme 3β

-hydroxysteroid dehydrogenase to treat or prevent at least one sign of cutaneous ageing.

2. The composition according to claim 1, wherein the inhibitor of the enzyme 3β

-hydroxysteroid dehydrogenase is present in an amount of 0.00001 to 10 % by weight with respect to the total weight of the composition.

3. The composition according to claim 1, wherein the inhibitor of the enzyme 3β

-hydroxysteroid dehydrogenase is selected from the isoflavones and isoflavans.

4. The composition according to claim 1, comprising daidzein or genistein.

5. The composition according to claim 1, comprising Equol or 5-hydroxy Equol.

6. The composition according to claim 1, wherein in that the inhibitor of the enzyme 3β

-hydroxysteroid dehydrogenase is selected from the group consisting of Epostane, Trilostane, 11-α

-bromoacetoxy-progesterone, 11-alkyl derivatives of progesterone, derivatives of 3 or 4 ketosteroids, RU486 and N,N-dimethyl-4-methyl-3-oxo-4-aza-5-androstane-17-β

-carboxamide (4-MA).

7. The composition according to claim 1, wherein the inhibitor of the enzyme 3β

-hydroxysteroid dehydrogenase is selected from the group consisting of cholesterol, its esters and its derivatives, 16-α

-hydroxydehydroepiandrosterone, 17β

-estradiol, ethynylestradiol, chloramidone acetate, and cyanotrimethylandrostenolone.

8. The composition according to claim 1, further comprising one or more natural or synthetic hormones selected from the group consisting of estrogenic, progestative and androgenic hormones.

9. The composition according to claim 1, further comprising a hormone selected from the group consisting of progesterone, estradiol, testosterone, broparestrol, estrone, pregnenolone acetate, pregnenolone, 17β

-hydroxyprogesterone, testosterone propionate, androstene and the androstanediols.

10. The composition according to claim 1, further comprising molecules and/or mimetic plant extracts of estradiol and/or progesterone.

11. The composition according to claim 1, further comprising RHEA and/or RHEA sulfate and/or 7 OH-RHEA and/or 7-keto-DHEA and/or 3β

-acetoxy-7-oxo-RHEA.

12. The composition according to claim 1, wherein said composition is in the form of an aqueous, alcoholic or aqueous-alcoholic solution or suspension or an oily suspension or a solution or dispersion of the lotion or serum type, an emulsion of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or the reverse (W/O), or a suspension or emulsion of soft consistency of ,the cream type (O/W) or (W/O), or an aqueous or anhydrous gel, an ointment, a free-flowing or compacted powder or in the form of microcapsules or microparticles, or vesicular dispersions of the ionic and/or nonionic type.

13. The composition according to claim 12, wherein the composition further comprises at least one liquid or solid fatty material selected from the group consisting of mineral oils, vegetable oils, animal oils, synthetic oils, siliconized oils or waxes, fluorinated oils, beeswax, Carnauba wax or paraffin wax, fatty acids, the fatty alcohols and the waxes.

14. The composition according to claim 1, further comprising one or more adjuvants selected from the group consisting of hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, bactericidal agents, odour absorbents and colouring matters.

15. The composition according to claim 1, further comprising a hydrophilic gelling agents selected from the group consisting of carboxyvinyl polymers, acrylic copolymers, polyacrylamides, polysaccharides, natural gums and clays.

16. The composition according to claim 1, further comprising an active agent selected from the group consisting of retinoids, α

-hydroxyacids, β

-hydroxy-acids, α

-keto-acids, β

-ketoacids, peroxides, vitamins, anti-radical active agents, selenium, zinc and β

-carotene.

17. The composition according to claim 1, further comprising an agent selected from the group consisting of modified clays, metal salts of fatty acids, ethylcellulose and polyethylene.

18. A method of achieving cellular renewal and/or improving the density of the fibrous macromolecules of the dermis, comprising topically applying or orally administering to a human the composition of claim 1.

19. A method of regulating the synthesis and/or degradation of the matrix proteins of the dermis, comprising topically applying or orally administering to a human the composition of claim 1.

20. A method of treating the slackening of the cutaneous and subcutaneous tissues, comprising topically applying or orally administering the composition of claim 1 to a human.

21. A method for brightening the lustre of the skin and/or reducing wrinkles and lines of the skin, comprising topically applying or orally administering the composition of claim 1 to a human.

22. A method for regulating the pigmentation processes of the skin and exoskeleton and/or the seborrhea and/or the growth of hair and/or body hair and/or nails, comprising topically applying or orally administering the composition of claim 1 to a human.